Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial

Marcel Hochreiter, Thomas Köhler, Anna Maria Schweiger, Fritz Sixtus Keck, Berthold Bein, Tilman von Spiegel, Stefan Schroeder, Marcel Hochreiter, Thomas Köhler, Anna Maria Schweiger, Fritz Sixtus Keck, Berthold Bein, Tilman von Spiegel, Stefan Schroeder

Abstract

Introduction: The development of resistance by bacterial species is a compelling issue to reconsider indications and administration of antibiotic treatment. Adequate indications and duration of therapy are particularly important for the use of highly potent substances in the intensive care setting. Until recently, no laboratory marker has been available to differentiate bacterial infection from viral or non-infectious inflammatory reaction; however, over the past years, procalcitonin (PCT) is the first among a large array of inflammatory variables that offers this possibility. The present study aimed to investigate the clinical usefulness of PCT for guiding antibiotic therapy in surgical intensive care patients.

Methods: All patients requiring antibiotic therapy based on confirmed or highly suspected bacterial infections and at least two concomitant systemic inflammatory response syndrome criteria were eligible. Patients were randomly assigned to either a PCT-guided (study group) or a standard (control group) antibiotic regimen. Antibiotic therapy in the PCT-guided group was discontinued, if clinical signs and symptoms of infection improved and PCT decreased to <1 ng/ml or the PCT value was >1 ng/ml, but had dropped to 25 to 35% of the initial value over three days. In the control group antibiotic treatment was applied as standard regimen over eight days.

Results: A total of 110 surgical intensive care patients receiving antibiotic therapy after confirmed or high-grade suspected infections were enrolled in this study. In 57 patients antibiotic therapy was guided by daily PCT and clinical assessment and adjusted accordingly. The control group comprised 53 patients with a standardized duration of antibiotic therapy over eight days. Demographic and clinical data were comparable in both groups. However, in the PCT group the duration of antibiotic therapy was significantly shorter than compared to controls (5.9 +/- 1.7 versus 7.9 +/- 0.5 days, P < 0.001) without negative effects on clinical outcome.

Conclusions: Monitoring of PCT is a helpful tool for guiding antibiotic treatment in surgical intensive care patients. This may contribute to an optimized antibiotic regimen with beneficial effects on microbial resistance and costs in intensive care medicine. ANNOTATION: Results were previously published in German in Anaesthesist 2008; 57: 571-577 (PMID: 18463831).

Trial registration: ISRCTN10288268.

Figures

Figure 1
Figure 1
Sequential Organ Failure Assessment scores. No difference in score was seen between patients with procalcitonin-guided antibiotic treatment (filled columns) and the control group (empty columns). Mean ± standard deviation. SOFA = Sequential Organ Failure Assessment.
Figure 2
Figure 2
Leukocyte values. No difference in values was seen between patients with procalcitonin-guided antibiotic treatment (filled columns) and the control group (empty columns). Mean ± standard deviation.
Figure 3
Figure 3
IL-6 concentrations. No difference in concentration was seen between patients with procalcitonin-guided antibiotic treatment (filled columns) and the control group (empty columns). Mean ± standard deviation.
Figure 4
Figure 4
C-reactive protein concentrations. No difference in concentration was seen between patients with procalcitonin-guided antibiotic treatment (filled columns) and the control group (empty columns). Mean ± standard deviation. CRP = C-reactive protein.
Figure 5
Figure 5
Procalcitonin concentrations. No difference in concentration was seen between patients with procalcitonin (PCT)-guided antibiotic treatment (filled columns) and the control group (empty columns). Mean ± standard deviation.
Figure 6
Figure 6
Procalcitonin levels solely shown for the intervention arm. In the group with procalcitonin (PCT)-guided antibiotic therapy duration, the PCT values starting on the fourth day are significantly lower in comparison to the initial value (box-plots with lower quartile, median and upper quartile, 0.1- and 0.9-quantile for the whisker length and outliers as item representation). • = Outliers, *P

References

    1. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596. doi: 10.1097/01.CCM.0000217961.75225.E9.
    1. ACCP/SCCM Consensus Conference Committee Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–874.
    1. Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinkart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med. 1999;37:363–368. doi: 10.1515/CCLM.1999.060.
    1. Peres Bota D, Lopes Ferreira F, Mélot C, Vincent JL. Body temperature alterations in the critically ill. Intensive Care Med. 2004;30:811–816. doi: 10.1007/s00134-004-2166-z.
    1. Bossink A, Groeneveld A, Hack C, Thijs L. The clinical host response to microbial infection in medical patients with fever. Clin Infect Dis. 1999;29:398–407. doi: 10.1086/520222.
    1. Christ-Crain M, Müller B. Procalcitonin in bacterial infections – hype, hope, more or less? Swiss Medical Weekly. 2005;135:451–460.
    1. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J, Geneva Sepsis Network Diagnostic value of procalcitonin, interleukin 6 and interleukin 8 in critically ill patiens admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164:396–402.
    1. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B. Procalcitonin guidance of antibiotic therapy in community – acquired pneumonia. Am J Respir Crit Care Med. 2006;174:84–93. doi: 10.1164/rccm.200512-1922OC.
    1. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients. A randomized trial. Am J Respir Crit Care Med. 2008;177:498–505. doi: 10.1164/rccm.200708-1238OC.
    1. Welte T. Antibiotikatherapie bei Sepsis. Dtsch Med Wochenschr. 2004;129:2609–2613. doi: 10.1055/s-2004-836084.
    1. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588–2598. doi: 10.1001/jama.290.19.2588.
    1. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162:505–511.
    1. Yu V, Singh N. Excessive antimicrobial usage cause measurable harm to patients with suspected ventilator – associated pneumonia. Intensive Care Med. 2004;30:735–738. doi: 10.1007/s00134-004-2201-0.
    1. Harbarth S. Antibiotikatherapie – Einfluss des Antibiotikaverbrauchs auf Resistenzbildung und – selektion. Anästhesiol Intensivmed Schmerzther. 2007;2:130–135. doi: 10.1055/s-2007-971165.
    1. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Caladra T, Glauser MP, Tauber MG, Pittet D. Fungal Infection Network of Switzerland. Epidermiology of candidemia in Swiss tertiary care hospitals: seculare trends, 1991–2000. Clin Infect Dis. 2004;38:311–320. doi: 10.1086/380637.
    1. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–710. doi: 10.1007/BF01709751.
    1. Engelmann L. Die Diagnose der Sepsis. In: Engelmann L, Schuster H-P, editor. Diagnostik und Intensivtherapie bei Sepsis und Multiorganversagen. 1. Darmstadt: Steinkopff; 2006. pp. 2–10.
    1. Meisner M, Tschaikowsky K, Palmaers T, Schmidt J. Comparison of Procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of Sepsis and MODS. Critical Care. 1999;3:45–50. doi: 10.1186/cc306.
    1. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K. Epidemiology of sepsis in Germany: Results from a national prospective multicenter study. Intensive Care Med. 2007;33:606–618. doi: 10.1007/s00134-006-0517-7.
    1. Micek S, Heuring TJ, Hollands JM, Shah RA, Kollef MH. Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy. 2006;26:204–213. doi: 10.1592/phco.26.2.204.
    1. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262–268. doi: 10.1378/chest.122.1.262.
    1. Meyer E, Jonas D, Schwab F, Gastmeier P, Rüden H, Daschner FD. SARI: surveillance of antibiotic use and bacterial resistance in German intensive care units. Correlation between antibiotic use and the emergence of resistance. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004;47:345–351. doi: 10.1007/s00103-004-0804-9.
    1. Welte T. Die nosokomiale Pneumonie. Intensivmed. 2006;43:301–309. doi: 10.1007/s00390-006-0721-2.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir